Table of contents

  • Psoriasis - Access & Reimbursement - Detailed, Expanded Analysis (US)

Author(s): Colleen E. Albacker, PhD; Chris Lewis

Colleen E. Albacker, Ph.D., is a director with the Immune and Inflammatory Disorders group at Decision Resources Group, where she comanages a team of analysts generating syndicated market research content. She has authored market research reports analyzing physician, payer, and market trends in respiratory indications, including asthma and COPD.

Prior to joining Decision Resources Group, Dr. Albacker conducted her graduate research on chromatin-modifying factors in zebrafish cancer and hematopoietic development at Harvard Medical School and Boston Children’s Hospital. She also gained experience with market research through a fellowship with the Harvard Office of Technology Development. Dr. Albacker holds a Ph.D. in genetics from Harvard University and a B.S. in biology with honors from the Pennsylvania State University.

Chris Lewis serves as primary research manager, U.S. Access and Reimbursement, with responsibility for coordination, content review and content generation of the market access and reimbursement insights at DRG. Content is based on online surveys of managed care organizations and physicians and expert analysis of reimbursement and prescribing patterns of key therapies treating various disease states.

Lewis was an analyst/senior analyst for the group’s HealthLeaders-InterStudy subsidiary for eight years, specializing in the managed care and pharmacy benefit management industries. Throughout her tenure, she has produced the Health Plan Analysis reports for California, New York, New Jersey, Connecticut, and Pennsylvania and authored DRG’s series of pharmacy benefit manager profiles. She has also conducted numerous webinars for the group. She is a seasoned journalist with a B.A. in communications from California State University, Sacramento.


Related Reports

Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

View Details

Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue...

View Details

Psoriasis - Current Treatment - Detailed, Expanded Analysis (EU5)

Multiple treatment options

View Details

Psoriasis - Emerging Therapies - Skyrizi Launch Tracking Wave 3 (US)

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Jan...

View Details